StimLabs and Geistlich Collaboration Overview
StimLabs, a prominent leader in regenerative medicine, is thrilled to announce an expansion of its partnership with Geistlich, a well-respected name in the regenerative medicine domain. Their partnership originally took shape in 2024 through an exclusive national distribution agreement aimed at introducing a groundbreaking wound care product line. This collaboration began with Derma-Gide, an advanced wound matrix, and has now evolved into a joint effort to develop a novel wound care solution that targets unmet medical needs.
Details of the New Product Launch
Expected to be available in Q2 2026, this innovative product represents the culmination of Geistlich's scientific prowess combined with StimLabs' commercial acumen. John Daniel, the Founder and CEO of StimLabs, expressed excitement about this next step, emphasizing the quality and innovative spirit embodied by Geistlich. Daniel stated, "Geistlich has continued to demonstrate their skill in innovation and commitment to quality, which are core values at StimLabs. We look forward to working with them to bring another unique solution to our patients and providers."
Core Values and Mission Behind the Partnership
At the heart of this collaboration lies a shared mission: to enhance patient quality of life through innovative regenerative solutions. Diego Gabathuler, CEO of Geistlich, highlighted the importance of merging scientific excellence with clinical trust. He shared, "We believe in combining scientific excellence with clinical trust to deliver innovations that truly make a difference for patients worldwide." This sentiment reinforces the commitment both companies share towards improving healthcare outcomes.
Future of Regenerative Medicine
As the partnership unfolds, both companies remain committed to pushing the envelope in regenerative medicine. David Wemans, VP of Regenerative Technologies at Geistlich, underscores this sentiment by stating, "By leveraging our research innovation with StimLabs' commercial strength, this partnership is poised to set new standards in regenerative medicine." This approach of combining innovative research with practical application aims to create solutions that truly address the needs of clinicians and patients alike.
About StimLabs
StimLabs stands at the forefront of regenerative medicine, focusing on both wound care and surgical applications. With a team of seasoned professionals, StimLabs prioritizes superior patient care and responds to urgent needs in healthcare. Their diverse product portfolio addresses various clinical applications, supported by a strong intellectual property portfolio. This commitment to excellence solidifies StimLabs as a reliable partner for healthcare providers and patients.
About Geistlich
With a legacy spanning 175 years in regenerative medicine, Geistlich holds a unique position in the market. The company focuses on high-quality Swiss manufacturing and offers comprehensive support to clinicians through scientific research and innovation. As a family-owned business established in 1851, Geistlich boasts a global presence with 15 affiliates and 60 distributors, servicing around 90 markets and employing over 800 individuals devoted to advancing regenerative medicine.
Frequently Asked Questions
What is the focus of the collaboration between StimLabs and Geistlich?
The collaboration focuses on developing a novel wound care product leveraging both companies' strengths in innovation and commercial expertise.
When is the new product expected to launch?
The new wound care product is anticipated to be available in Q2 2026.
What is StimLabs' mission in regenerative medicine?
StimLabs aims to provide superior regenerative medicine solutions, particularly in wound care and surgical applications, meeting urgent healthcare needs.
How long has Geistlich been in the regenerative medicine field?
Geistlich has 175 years of experience in regenerative medicine, contributing significantly to advancements in the field.
Can the public expect more innovative products from this partnership?
Yes, both companies are committed to pushing the boundaries of regenerative medicine and delivering innovative products that improve patient outcomes.
